Eric Lefebvre - 29 Mar 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
Chief Medical Officer
Signature
/s/ Mike Ouimette, attorney-in-fact
Issuer symbol
PLRX
Transactions as of
29 Mar 2023
Transactions value $
$0
Form type
4
Filing time
31 Mar 2023, 18:02:11 UTC
Previous filing
27 Jan 2023
Next filing
03 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Award $0 +21.9K +16.18% $0.00 157K 29 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,874 shares.
F2 Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.